This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Oral bolus of vitamin D at admission failed to improve overall COVID-19 outcomes

An oral bolus of 100,000 IU of vitamin D given to patients with COVID-19 upon admission to hospital was of no overall benefit

The use of a large oral bolus of cholecalciferol (vitamin D) given to patients with moderate-to-severe COVID-19 upon admission to a hospital failed to improve overall outcomes compared with no treatment.

This was the conclusion of a large, randomised trial by researchers from the Hospital Universitario Central de Asturias (HUCA), Avda. Roma, Spain. However, in a separate subgroup analysis, it did appear that there were positive benefits among those with higher baseline calcidiol levels upon admission.

An inverse relationship has been established between vitamin D levels and the development of several autoimmune diseases although whether this effect on the immune system has a positive impact upon the body’s ability to fight respiratory infections and on chronic diseases is currently uncertain.

Much has been written on the potential benefits of vitamin D among patients with COVID-19 and one systematic review concluded that low vitamin D levels represent an increased risk of acute respiratory distress syndrome, admission to an intensive care unit or mortality due to COVID-19 infection.

Nevertheless, a limitation from the aforementioned systematic review, it how the data were derived from observational studies and there has been a distinct absence of randomised, controlled trials, which can provide more robust evidence.

For the present study, the Spanish team undertook a randomised trial (COVID-VIT-D) to investigate whether a single, large, oral bolus of 100,000 IU of cholecalciferol given upon admission to hospital, could impact on the outcomes associated with a COVID-19 infection.

Eligible patients (18 years and over) were those hospitalised for moderate-to-severe COVID-19 infection and who were randomised 1:1, to receive a single oral bolus of cholecalciferol or nothing. Patients were followed from admission until discharge and demographic, co-morbidity, biochemical, imaging results and all treatments used were recorded.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

The three primary outcomes for the trial were: length of hospitalisation; admission to an intensive care unit (ICU) and mortality. In a separate cohort analysis, the researchers examined the relationship between serum calcidiol upon admission with pulmonary involvement and the same three primary outcomes of the trial.

Single oral bolus and COVID-19 outcomes

A total of 543 patients with a median age of 58 years (65% male) were randomised to vitamin D (274) or nothing. The most frequent co-morbidities were hypertension (43.8%), diabetes (24.7%) and cardiovascular disease (21.2%). In addition, pulmonary involvement was diagnosed in 83.1% of those upon admission.

With respect to the primary outcomes, there were no differences between the two groups. The median length of hospital stay was 10 vs 9.5 days (vitamin D vs control), admission to ICU (172.% vs 16.4%) and mortality (8% vs 5.6%).

When considering the lowest (< 10ng/ml) and highest(> 25 ng/ml) baseline levels, the presence of a higher calcidiol level was associated with a lower risk of pulmonary involvement upon admission (odds ratio, OR = 0.21, 95% CI 0.08 – 0.60) and a lower risk of ICU admission (hazard ratio, HR = 0.35, 95% CI 0.13 – 0.95). However, baseline calcidiol levels had no effect on the length of hospitalisation or mortality.

The authors concluded that while a single oral bolus of vitamin D did not improve overall outcomes for those hospitalised with COVID-19, higher baseline calcidiol levels did appear to have better outcomes.

Cannata‐Andía JB et al. A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial BMC Med 20222